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Abstract
 
Inhibitory receptors CD22, Fc
 
 
 
RII (CD32), CD72, and paired immunoglobulin-like receptor
(PIR)-B are critically involved in negatively regulating the B cell immune response and in pre-
venting autoimmunity. Here we show that interleukin 4 (IL-4) reduces expression of all four
on activated B cells at the level of messenger RNA and protein. This reduced expression is de-
 
pendent on continuous exposure to IL-4 and is mediated through Stat6. Coligation of Fc
 
 
 
RII to
the B cell receptor (BCR) via intact IgG increases the B cell activation threshold and suppresses
antigen presentation. IL-4 completely abolishes these negative regulatory effects of Fc
 
 
 
RII.
CD22 coligation with the BCR also suppresses activation — this suppression too is abolished
by IL-4. Thus, IL-4 is likely to enhance the B cell immune response by releasing B cells from
inhibitory receptor suppression. By this coordinate reduction in expression of inhibitory recep-
tors, and release from CD22 and Fc
 
 
 
RII-mediated inhibition, IL-4 is likely to play a role in T
cell help of B cells and the development of T helper cell type 2 responses. Conversely, B cell
activation in the absence of IL-4 would be more difficult to achieve, contributing to the main-
tenance of B cell tolerance in the absence of T cell help.
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Introduction
 
Activation of peripheral B cells is inhibited by a number of
cell surface molecules such as CD22, Fc
 
 
 
RII (CD32),
CD72, and paired immunoglobulin-like receptor (PIR)-B.
Little is known about what releases the B cell from this in-
hibitory thrall, allowing it be appropriately activated in
response to pathogens, and inappropriately activated by self-
antigen resulting in autoimmunity. These inhibitory recep-
tors contain immune tyrosine inhibitory motifs (ITIMs) in
their cytoplasmic tails which, under specific circumstances,
such as when Fc
 
 
 
RII and CD22 are coligated with the B
cell receptor (BCR), are phosphorylated by the tyrosine ki-
nase lyn. ITIM motifs can then dock with the SH2 do-
mains of phosphatases – predominantly SH2-containing
protein tyrosine phosphatase Shp-1 (CD22, CD72, and
PIR-B), and the inositol phosphatase SH2-containing inos-
itol 5-phosphatase (SHIP; Fc
 
 
 
RII). These phosphatases
then dephosphorylate incompletely defined downstream
targets and reduce cellular activation (1).
Consistent with the similarity in the signaling pathways
of Fc
 
 
 
RII, CD22, and CD72, mice deficient in them dis-
play defects in their antibody responses. These include in-
creased serum IgG and IgM and increased B cell respon-
siveness to antigen (2–4). Moreover, mice deficient in lyn
or Shp-1, molecules responsible for the signaling of the
ITIM-containing inhibitory receptors, also exhibit evi-
dence of B cell hyperactivity (5). Fc
 
 
 
RII is ligated to the
BCR by antigen and IgG in immune complexes, and may
therefore provide feedback inhibition. Coligation of CD22
to the BCR reduces B cell activation, while sequestering
CD22 away from the BCR results in B cell hyperactivity
(for a review, see reference 5). Interaction of CD22 with its
sialic acid residue ligand may promote B cell activation in
appropriate lymphoid environments (5) and/or reduce the
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likelihood of autoreactivity (6). Ligands for CD72 may in-
clude CD5 and CD100 (4), and for PIR-B, MHC I (7),
though their exact roles in B cell regulation are yet to be
determined. An activatory version of PIR-B, PIR-A, is
also expressed on B cells. Both these molecules share essen-
tially identical extracellular domains and it is thought that
their ratio on the B cell surface may determine their net ef-
fect on activation (8).
Not only are the ITIM-containing inhibitory receptors
important in controlling the B cell response to exogenous
antigen, they also appear to be important in maintaining
self-tolerance. Mice deficient in Fc
 
 
 
RII, CD22, lyn, or
Shp-1 all display a predisposition to autoimmunity (5, 9,
10). Partial defects in these molecules may contribute to
the development of spontaneous systemic lupus erythema-
tosus (SLE)-like disease in polygenic models, with Fc
 
 
 
RII
being implicated in SLE in a number of mouse models
(11), CD22 in the NZW mouse (12), and CD72 in the
MRL mouse (13).
Relatively small reductions in expression of these mole-
cules can result in increased B cell activation and/or a con-
tribution toward the breakdown of self-tolerance. Thus, a
defect in tolerance in the hen egg lysozyme (HEL)/anti-
HEL system occurs in mice heterozygous for lyn, CD22,
and SHP-1 (14). In addition, mice heterozygous for dele-
tions in Fc
 
 
 
RII or CD22 exhibit only modest reductions
in protein expression, but nonetheless have a reduced but
significant predisposition to autoimmunity (J. Ravetch,
personal communication; and reference 12). The normal
regulation of surface expression of inhibitory receptors is
therefore likely to be important in controlling the outcome
of B cell activation in both normal and autoreactive im-
mune responses.
IL-4 is produced predominantly by T cells and has many
effects, as the IL-4R is widely expressed (reviewed 15).
Most of the IL-4–mediated effects on lymphocytes, includ-
ing the mitogenic effect, are reduced or abolished in Stat6-
deficient mice (15). B cell effects of IL-4 include isotype
switching to IgG1 and IgE (in the mouse, IgG4 and IgE in
humans), increased expression of MHC II, CD23, and the
IL-4R, prevention of apoptosis in culture (for a review, see
reference 15), and morphological changes (16). Impor-
tantly, IL-4 increases B cell proliferation when acting in
concert with other activatory signals, but does not have this
effect alone (17). The mechanisms by which IL-4 stimula-
tion promotes B cell proliferation and activation are not
well defined.
Here we show that signals through the IL-4R reduce the
expression and function of ITIM-containing inhibitory re-
ceptors on activated B cells, suggesting the release of the B
cell from ITIM-mediated suppression is likely be an impor-
tant mechanism of action of IL-4.
 
Materials and Methods
 
Mice.
 
C57BL/6 Fc
 
 
 
RII
 
 
 
/
 
 
 
 mice (3) were provided by Jeff
Ravetch and Silvia Bolland (The Rockefeller University, New
York, NY). C57BL/6 Stat6
 
 
 
/
 
 
 
 mice were provided by Eva Sev-
 
erinson (Karolinska Institute, Stockholm, Sweden). Control mice
were from Charles River Laboratories.
 
Cell Purification and Stimulation.
 
Splenic B cells were selected
by magnetic cell purification using anti-CD19 beads (Miltenyi
Biotech), to 
 
 
 
95% purity. Results were confirmed by negative
selection using anti-CD43 beads (Miltenyi Biotech). Cells were
cultured (2 
 
 
 
 10
 
6
 
 cells/ml) in 24-well flat bottomed plates
(Corning Inc.) in RPMI-1640 (Sigma-Aldrich) and 10% fetal calf
serum (Invitrogen) and stimulated with either goat anti–mouse
IgM 
 
 
 
-chain specific F(ab
 
 
 
)
 
2
 
 or intact IgG (Jackson ImmunoRe-
search Laboratories) or LPS (Sigma-Aldrich). Cytokines added to
these cultures were IL-4 (usually 10 ng/ml: PeproTech), IL-2, 5,
6, 9, and 13 (all 10 ng/ml), IL-10 (100 ng/ml), IFN-
 
 
 
 (1,000
U/ml; R&D Systems), and TGF
 
 
 
 (PeproTech). CD40L express-
ing J558L cells were the gift of Prof. Martin Glennie (University
of Southampton, Southampton, UK). Rat anti–mouse IL-4 neu-
tralizing antibody (Serotec) or isotype control (Caltag) were used
at 30 
 
 
 
g/ml.
 
Flow Cytometric Analysis and Intracellular Calcium ([Ca
 
2
 
 
 
]i) Mea-
surement.
 
Cells were stained with FITC-conjugated 2.4G2
(anti-Fc
 
 
 
RII/III), anti-CD22, anti-CD72, or isotype control
(BD PharMingen) and counterstained with RA6–3B2 (anti-B220
PE) and 7-aminoactinomycin D (Molecular Probes) to identify B
cells and exclude dead cells respectively. Cells were analyzed us-
ing a FACSCalibur™ flow cytometer (Becton Dickinson) and
FCS Press software (Ray Hicks, University of Cambridge, Cam-
bridge, UK). To determine [Ca
 
2
 
 
 
]i flux, B cells from three mice
were pooled, purified, and stimulated for 48 h with LPS (10 
 
 
 
g/
ml) with or without IL-4 (10 ng/ml). They were then prepared
and loaded with Indo-1 as described (11) before staining and
analysis using a FACS Vantage™ flow cytometer (Becton Dick-
inson). Thapsigargin (100 ng/ml; Molecular Probes) stimulation
was used to confirm equality of maximal responsiveness and
Indo-1 loading (not shown).
 
Real Time Semiquantitative Reverse Transcription-PCR.
 
RNA
was extracted from equal numbers of B cells using TRIzol
 
® 
 
Re-
agent (GIBCO BRL), and reverse transcribed using Super RT
(HT Biotechnology). Levels of Fc
 
 
 
RII, CD22, CD72, PIR-B,
PIR-A, IL-2R
 
 
 
 chain, and CD23 mRNA were assessed relative
to GAPDH using real time semiquantitative reverse transcrip-
tion (RT)-PCR (ABI Prism 7700 Sequence Detection System;
Applied Biosystems). The GAPDH control primers and probe
were Taqman Rodent control reagents (Applied Biosystems).
IL-2R
 
 
 
 chain primers and probe were supplied by Dr. A.
Gonzalea-Munoz (University of Cambridge), and all other
primers and probes were designed using Primer Express software
(Applied Biosystems) and manufactured by Sigma-Genosys and
Biosource International.
 
Proliferation Assays.
 
 Purified B cells (2 
 
 
 
 10
 
6
 
/ml) were stimu-
lated with anti-IgM 
 
 
 
-chain specific F(ab
 
 
 
)
 
2
 
 or intact antibody
(Jackson ImmunoResearch Laboratories). Tritiated thymidine
(0.5 
 
 
 
Ci; Amersham Pharmacia Biotech) was added from 24 to
48 h and incorporation determined using a scintillation counter
(Packard Bioscience).
 
Antigen Presentation Assay.
 
Purified B cells from BALB/C
 
 
 
/
 
 
 
and control mice were cultured (10
 
6
 
/ml) with the ovalbumin
specific T cell hybridoma D011.10 (18) at 2.5 
 
 
 
 10
 
5
 
/ml. Oval-
bumin or bovine serum albumin (negative control; Sigma-
Aldrich) was added at either 2 and 10 mg/ml. Cells were stimu-
lated with anti IgM F(ab
 
 
 
)
 
2
 
 or intact antibody, either alone or
with 2.4G2 (5 
 
 
 
g/ml) or murine IL-4 (10 ng/ml), for 24 h at
37
 
 
 
C. IL-2 was then assayed using a sandwich ELISA (Becton
Dickinson). 
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Results
 
IL-4 Reduces Expression of Fc
 
 
 
RII, CD22, and CD72 on
Activated B Cells.
 
Regulation of ITIM-containing inhibi-
tory receptors is likely to be important both in controlling
the normal immune response, and in preventing the devel-
opment of autoimmunity. IL-4 has previously been shown
to reduce Fc
 
 
 
RII binding on activated B cells (19). We
sought to study the influence of IL-4 and other cytokines
on B cells, further characterizing the effect on Fc
 
 
 
RII ex-
pression, and determining if expression of other inhibitory
receptors was similarly controlled. Splenic B cells were ac-
tivated with anti-IgM F(ab
 
 
 
)
 
2
 
 fragments in the presence of
IL-4, other cytokines, or medium alone. IL-4 had no effect
on expression if cultured with unstimulated B cells, but
upon B cell activation a progressive relative reduction of
Fc
 
 
 
RII, CD22, and CD72 could be seen relative to B cells
activated in medium alone (Fig. 1 A). This effect was con-
sistently seen (Fig. 1 B), and was also seen if the B cells
were activated by LPS in place of anti-IgM (data not
shown). Expression of the inhibitory receptors was not in-
fluenced when B cells were activated in the presence of
IL-2, 3, 5, 6, 9, 10, or 13, TGF-
 
 
 
, TNF-
 
 
 
, IFN-
 
 
 
, or
CD40-ligand expressing J558L (data not shown). The ef-
fect of IL-4 could be titrated, and its specificity was con-
firmed by blocking with neutralizing anti–IL-4 antibodies
(data not shown). Reduction in inhibitory receptor expres-
sion required constant exposure of the B cell to IL-4, as re-
moval of the latter after 24 h by washing (Fig. 1 C) or addi-
tion of neutralizing anti–IL-4 antibodies (data not shown)
resulted in rapid restitution of inhibitory receptor levels to
normal. Once the B cell had been activated in the absence
of IL-4, subsequent addition of IL-4 could still reduce in-
hibitory receptor expression (Fig. 1 C). Thus the reduction
in inhibitory receptor expression caused by IL-4 requires
constant exposure to it, and is not “set” at the time of ini-
tial activation of the B cell.
Resting splenic B cells were labeled with 5-(and-6)-car-
boxyfluorescein (CFSE). IL-4 increased B cell proliferation
(indicated by reduced CFSE staining), but when gates were
placed upon B cells having undergone similar numbers of
divisions, reduction in inhibitory receptor expression in the
IL-4–treated population could still be clearly seen relative
to control (data not shown). Similar experiments showed
that in B cells expressing similar levels of CD69 or CD86,
the effect of IL-4 on inhibitory receptor expression was still
observed (data not shown). Activated B cells did not ex-
press the plasma cell marker CD138 (syndecan). Thus, re-
duced inhibitory receptor expression is specifically depen-
dent on IL-4, and is not the nonspecific consequence of
increased proliferation or differentiation.
 
IL-4 Reduces Levels of Fc
 
 
 
RII, CD22, CD72, and PIR-B
mRNA in Activated B Cells, but Increases PIR-A.
 
A marked
reduction in CD22, Fc
 
 
 
RII, and CD72 mRNA levels was
seen as early as 24 h after activation in the presence of IL-4
(Fig. 2), a time at which little difference is seen in surface
Figure 1. IL-4 reduces surface
expression of inhibitory recep-
tors on activated B cells. (A) Pu-
rified splenic B cells were acti-
vated with anti-IgM F(ab )2
antibodies with (closed circles)
or without (closed squares) IL-4.
Levels of expression of Fc RII,
CD22, and CD72 were deter-
mined by flow cytometry at the
times shown. Isotype control
staining is shown (open squares).
Variation in control bead mean
channel fluorescence was    5%
between time points (not
shown). (B) Expression levels at
72 h for seven experiments. In-
dividual symbols correspond to
single experiments. Mean ex-
pression (horizontal bars) of all
three molecules was significantly
lower when activation occurred
in the presence of IL-4 (**P  
0.005, Mann-Whitney U test).
(C) B cells were activated with
anti-IgM F(ab )2 in the continu-
ous presence (closed circles) or
absence (closed squares) of IL-4.
In addition, in some cultures IL-4
was only added after 24 h
(open circles) or was added at
the start but removed at 24 h
(open squares). 
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expression (Fig. 1 A). In addition, a similar reduction in
PIR-B mRNA was observed (Fig. 2). Moreover, PIR-A
mRNA levels were increased by IL-4, and the PIR-A/B
ratio increased 17-fold. The relative ratio of PIR-A and B
in the membrane is thought to determine their net activa-
tory effect (8), as is true for a number of paired inhibitory/
activatory receptors, and thus this reciprocal regulation of
their expression would shift the B cell from an inhibitory
toward an activatory state.
 
The Effect of IL-4 on Inhibitory Receptor Expression Is Pre-
dominantly Mediated through Stat6.
 
Stat6 signaling is
known to mediate IL-4’s control of the expression of
MHC II, CD23, and the IL-4R, but the mechanism by
which Stat6 contributes to IL-4–mediated proliferation is
unclear. Experiments in Stat-6–deficient mice demon-
strated that the reduction in inhibitory receptor expression
caused by IL-4 is dependent on signaling through Stat6
(Fig. 3).
Possible mechanisms of IL-4/Stat6 suppression of inhib-
itory receptors include the production of inhibitory inter-
mediates such as the suppressors of cytokine signaling
(SOCS) proteins (20) or competition with nuclear factor
(NF)-
 
 
 
B (21). The promoter regions of the inhibitory re-
ceptors have not been exhaustively examined (but see Fc-
 
 
 
RII, [11]; CD22, [22]; CD72, [4]; PIR-B, [23]). None-
theless, there are a number of putative Stat binding
elements upstream of the start sites of all four inhibitory re-
ceptors examined in this study, though consensus se-
quences typical of those thought to preferentially bind
Stat6 (24) are only seen in CD22 and PIR-B. This raises
the additional possibilities that Stat6 could operate either
by direct binding to, or by competing with, other Stat
family members.
 
IL-4 Abolishes the Inhibitory Effect of Fc
 
 
 
RII Ligation on B
Cell Activation.
 
When the BCR is cross-linked by anti-
IgM F(ab
 
 
 
)
 
2
 
, B cells proliferate. Coligation of Fc
 
 
 
RII into
this BCR complex, for example by stimulation with intact
instead of F(ab
 
 
 
)
 
2
 
 anti-IgM IgG, reduces this proliferation.
IL-4 has been reported to overcome this inhibition (25).
We confirmed and extended these findings, demonstrating
that stimulation by intact IgG increased the threshold for B
Figure 2. IL-4 reduces mRNA expression of Fc RII, CD22, CD72,
and PIR-B, and increases PIR-A. B cells were cultured with anti-IgM
F(ab )2 with or without IL-4 for 24 h, RNA isolated and quantified rela-
tive to GAPDH by real time RT-PCR. Shown is the mean (  1 SD) of a
number of independent experiments (Fc RII, five experiments; CD22,
four experiments; CD72, six experiments; PIR-B, four experiments; and
PIR-A, three experiments). These means were significantly different from
levels in B cells cultured with anti-IgM F(ab )2 alone (**P    0.005,
Mann-Whitney U test). CD23 mRNA levels are shown as a positive
control and IL-2R  chain levels are shown as an example of an mRNA
little influenced by IL-4.
Figure 3. The reduction in inhibitory receptor expression caused by IL-4
is mediated by Stat6. B cells were activated by anti-IgM F(ab )2 with or
without IL-4 in C57BL/6 mice and in Stat6-deficient mice on the
C57BL/6 background. Average geometric mean channel fluorescence   1
SD of Fc RII, CD22, and CD72 on B cells from three individual mice
cultured for 48 h is shown. Representative one of two experiments shown.
Significant reductions in inhibitory receptor expression were seen in B
cells from control mice, but not in Stat /  mice (Mann-Whitney U test). 
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cell activation, and that this increase was dependent on Fc-
 
 
 
RII as it did not occur in Fc
 
 
 
RII-deficient mice. In the
presence of IL-4 the activation threshold was no longer in-
creased by recruitment of Fc
 
 
 
RII (Fig. 4 A). IL-4 also in-
duces a small but consistent reduction in activation thresh-
old that is independent of Fc
 
 
 
RII.
IL-4 Abolishes the Inhibitory Effect of Fc RII Ligation on B
Cell Antigen Presentation. Activated B cells can present an-
tigen to T cells, and such presentation is likely to be impor-
tant in maintaining T cell help to promote ongoing B cell
responses, and in maintaining an effective TH2 response. B
cell antigen presentation is increased in the presence of co-
stimulation through the BCR and this increase is reduced
by cross-linking Fc RII to the BCR (26). We confirmed
that, compared with activation by anti IgM F(ab )2, Fc RII
recruitment by intact anti-IgM reduced MHC II-restricted
presentation of fluid-phase OVA to the T cell hybridoma
DO11.10. This inhibition was Fc RII dependent, as it was
not seen if Fc RII was blocked by the mAb 2.4G2, nor in
Fc RII-deficient mice (Fig. 4 B). The addition of IL-4 re-
versed this inhibition: antigen presentation occurred as ef-
fectively in B cells stimulated by intact anti-IgM in the
presence of IL-4 as it did in those stimulated by anti-IgM
F(ab )2 alone (Fig. 4 B).
IL-4 Abolishes the Effect of CD22 Sequestration on B Cell
Intracellular Calcium Flux. Coligation of CD22 to the
BCR results in suppression of B cell activation (27), and
conversely sequestration of CD22 away from the BCR re-
sults in a reduced activation threshold (28) and enhanced
[Ca2 ]i flux (29). We examined the effect of CD22 seques-
tration on [Ca2 ]i concentrations. Upon BCR cross-link-
ing with anti-IgM F(ab )2, an exaggerated [Ca2 ]i response
was seen in those cells in which CD22 had been seques-
tered (Fig. 5). In cells which had been cultured in IL-4 for
48 h an enhanced response was seen whether or not CD22
Figure 4. IL-4 abolishes Fc-
 RII-mediated suppression of B
cell activation and antigen pre-
sentation. (A) Activation thresh-
old: B cells from control and
Fc RII-deficient mice were
stimulated with F(ab )2 or intact
anti-IgM antibody in the pres-
ence or absence of IL-4. In the
absence of IL-4, recruitment of
Fc RII by intact anti-IgM re-
sults in an increased activation
threshold. This is not seen if
Fc RII is not engaged – when
either F(ab )2 anti-IgM or
Fc RII /  B cells are used.
When B cells are activated in the
presence of IL-4, however, no
inhibitory effect of Fc RII is
seen (one of three experiments
shown). (B) Antigen presenta-
tion: B cells were stimulated for
24 h with F(ab )2 or intact anti-
IgM antibody with or without
IL-4 or 2.4G2, then incubated
with the T cell hybridoma
DO11.10 and soluble OVA. An-
tigen presentation by B cells to
the T cell line resulted in IL-2
production, measured by ELISA. Antigen presentation is suppressed in control B cells stimulated with intact anti-IgM when compared with Fc RII / 
B cells (left panel). This suppression is mediated by Fc RII, as it does not occur when Fc RII is blocked by the addition of 2.4G2 (central panel). The
addition of IL-4 (right panel) reverses the suppression of antigen presentation by intact anti-IgM as effectively as 2.4G2.
Figure 5. IL-4 abolishes CD22-mediated inhibition of [Ca2 ]i flux af-
ter stimulation through the BCR. B cells were stimulated for 48 h with
LPS either with (right panel) or without (left panel) IL-4, then loaded
with Indo-1 and stained with biotinylated anti-CD22 antibody. Changes
in FL5/FL4 fluorescence ratio are proportional to [Ca2 ]i and were mea-
sured by flow cytometry. After 30 s (A) either Kreb’s Ringer phosphate
solution/BSA (thin line) or avidin 1 mg/ml (thick line) was added. After a
further 210 s anti-IgM F(ab )2 was used to cross-link the BCR. Addi-
tional sequestration of CD22 with avidin released the B cells from inhi-
bition, as seen by increased [Ca2 ]i (left panel). In cells activated in the
presence of IL-4, sequestration of CD22 had no effect on [Ca2 ]i, indi-
cating no discernible suppression of [Ca2 ]i by CD22. Representative of
three experiments.1084 Interleukin 4 Reduces Negative Regulation of B Cells
was cross-linked, indicating that the suppressive effect of
CD22 was abolished by IL-4.
The IL-4–mediated decrease in inhibitory receptor ex-
pression and function provides a novel mechanism by
which IL-4 may enhance B cell activation. The reduction
would be expected to have a functional effect for at least
three reasons. First, the reduction in inhibitory receptors
caused by IL-4 is of the same degree as that seen in mice
heterozygous for deletions in individual inhibitory recep-
tors, which results in a significant phenotype (Fc RII; J.
Ravetch, personal communication, CD22; reference 12).
Second, it would be expected that a quantitatively similar
reduction in all four inhibitory receptors on activated B cells
would have an additive or synergistic effect on B cell func-
tion, as has been demonstrated in mice heterozygous for
CD22, lyn, and Shp-1 (14). Third, IL-4 completely abol-
ished the inhibitory effects of both CD22 and Fc RII on B
cell activation, and of Fc RII on antigen presentation. This
implies that continuous T cell production of IL-4 can over-
ride inhibitory signals, consistent with, though not directly
implicating, the observed reduction in their expression.
Thus, the reduction in inhibitory receptor expression
and function brought about by IL-4 could enhance T cell
driven B cell activation early in “undifferentiated” immune
responses (Th0), and could drive such activation in a more
prolonged fashion in Th2 responses. Reduction in negative
regulation by IL-4 may also help recruit ongoing T cell
help by permitting continued antigen presentation by B
cells not subject to Fc RII-mediated feedback. This ampli-
fying effect could account for the IL-4–dependent produc-
tion of very large amounts of IgG1 and IgE seen in Th2 re-
sponses, and in particular in allergy and in chronic parasitic
infections (15).
IL-4 could predispose to autoimmune disease, as it abol-
ishes CD22- and Fc RII-mediated inhibition, mice defi-
cient in either of these are prone to autoimmunity (2, 10),
and the observed reduction in four different inhibitory re-
ceptors are likely to have at least additive effects. Once tol-
erance had been breached, IL-4 production could override
Fc RII-mediated feedback mechanisms allowing contin-
ued production of autoantibody and the recruitment of
further T cell help. These possibilities are supported by
studies demonstrating that transgenic overexpression of IL-4
leads to an SLE-like illness in mice (30).
IL-4 reduces the expression of Fc RII, CD22, CD72,
and PIR-B, all ITIM-containing inhibitory receptors, on
activated B cells. In addition, IL-4 reverses the inhibitory
effect of CD22 on B cell activation, and of Fc RII on acti-
vation threshold and antigen presentation. This suggests a
new role for IL-4 in the T cell dependent B cell response –
in removal of ITIM-mediated suppression rather than
solely in direct activation.
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